Bayer’s FDA review extension for elinzanetant signals global push for hormone-free menopause therapies

The U.S. Food and Drug Administration (FDA) has extended its review of Bayer AG’s (ETR: BAYN) New Drug Application (NDA) for elinzanetant, a first-in-class dual neurokinin-1 and neurokinin-3 receptor antagonist, intended for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. The prescription drug user fee act (PDUFA) date has been extended by up to 90 days, with the agency requesting additional time for a full assessment of the NDA materials and data, including supplemental information recently submitted by Bayer.

Bayer emphasized that the FDA’s extension did not raise any concerns regarding the overall approvability of elinzanetant. This regulatory development, while procedural in nature, reflects growing global attention on menopause-related therapeutics—an area historically underserved despite its widespread impact on the quality of life of millions of women.

Why is Bayer pursuing a hormone-free hot flash treatment?

Elinzanetant represents a new class of non-hormonal treatments for vasomotor symptoms, commonly known as hot flashes and night sweats. These symptoms affect up to 80% of women during menopause, with about one-third experiencing them at moderate to severe levels. Traditionally, hormone replacement therapy (HRT) has been the dominant treatment pathway, but safety concerns, particularly around breast cancer and cardiovascular risk, have left a gap for alternative options.

Unlike HRT, elinzanetant acts by modulating central nervous system pathways—specifically neurokinin receptors—that are involved in the thermoregulatory instability associated with VMS. According to Bayer, this receptor-targeting approach provides a hormone-free therapeutic route for women who are contraindicated for estrogen therapy or prefer to avoid hormonal treatment.

The NDA for elinzanetant was built upon robust data from three pivotal Phase III trials—OASIS 1, 2, and 3. OASIS 1 and 2 were published in the Journal of the American Medical Association (JAMA) in August 2024, showing statistically significant reductions in both frequency and severity of hot flashes versus placebo. OASIS 3, presented at the 2024 Menopause Society annual meeting, provided additional long-term safety and efficacy data supportive of a favorable benefit-risk profile.

What does the extended FDA review mean for Bayer?

For Bayer, the FDA’s review extension slightly delays potential entry into the U.S. menopause therapeutics market but does not indicate any fundamental problem with the drug’s safety or efficacy. As highlighted by Dr. Yesmean Wahdan, Bayer Pharmaceuticals’ Senior Vice President and Head of Medical Affairs for North America, the company remains confident in elinzanetant’s clinical value and continues to collaborate closely with the agency.

The drug’s approval momentum in other major markets continues. Within the past month, elinzanetant was granted marketing authorization in the United Kingdom and Canada under the brand name Lynkuet. Regulatory filings are also under review in the European Union and multiple Asia-Pacific territories, suggesting Bayer’s strategy is focused on synchronized global market access for elinzanetant.

Investor sentiment toward Bayer’s women’s health business remains mixed, especially as the company navigates other pipeline delays and ongoing litigation in unrelated segments. However, analysts tracking the pharmaceutical sector view elinzanetant as a potential blockbuster in a category expected to grow to over $5 billion globally by 2030. The company’s diversification into hormone-free menopause management also aligns with broader industry trends, where non-hormonal innovation is gaining traction across chronic female health conditions.

How does elinzanetant fit into Bayer’s broader women’s health portfolio?

Elinzanetant is a critical pillar in Bayer’s long-term commitment to women’s healthcare, an area it has historically led with contraceptive innovations such as Mirena and Kyleena, and hormone therapy options for gynecological disorders. According to the company’s 2024 Women’s Health Progress Report, Bayer aims to reach 100 million women annually in low- and middle-income countries by 2030 with access to modern contraceptives—part of its sustainability-linked global health goals aligned with the United Nations Sustainable Development Goals.

The company’s current women’s health revenues exceed €1.8 billion annually, with its long-acting reversible contraceptives (LARCs) portfolio accounting for over 60% of that figure. Analysts suggest that elinzanetant could eventually represent a 10–15% incremental revenue contribution within the first five years post-launch, assuming successful rollout and reimbursement coverage in key markets.

In parallel, Bayer is also funding research collaborations and awareness campaigns to dismantle the stigma surrounding menopause and support informed healthcare decisions. Its emphasis on education, access, and innovation aims to create a comprehensive ecosystem around women’s midlife health.

What’s the competitive landscape for non-hormonal menopause therapies?

Bayer’s development of elinzanetant puts it in a race with other biopharma companies exploring non-hormonal treatments for VMS. Astellas Pharma’s Veozah (fezolinetant), approved by the FDA in 2023, was the first NK3 receptor antagonist to reach the U.S. market for menopause-related hot flashes. However, elinzanetant, as a dual NK1/NK3 inhibitor, could offer broader efficacy or differentiated safety once real-world evidence matures.

Pfizer and Organon are also reportedly exploring early-stage candidates in adjacent mechanisms, though they remain behind Bayer and Astellas in terms of regulatory progress. The current landscape is marked by intense interest from institutional investors in the female health innovation space, which has long been underfunded despite high prevalence conditions and significant quality-of-life burdens.

Market data shows that postmenopausal women in North America and Europe are increasingly seeking alternative therapies to HRT, especially those with cancer risk factors or prior cardiovascular events. Bayer’s elinzanetant could capture a significant share of this expanding segment, particularly if pricing strategies and insurance coverage align favorably with clinical value.

How are analysts interpreting the FDA extension?

While the extended review timeline introduces a mild delay, early investor reactions have remained neutral to cautiously optimistic. No concerns were flagged by the FDA on approvability grounds, and Bayer’s simultaneous approvals in other countries mitigate the commercial impact of the U.S. deferral. Some analysts note that such extensions are not uncommon when additional information is submitted late in the review cycle, especially in the context of first-in-class or novel mechanism compounds.

Equity research desks at firms like Jefferies and Berenberg continue to rate Bayer stock as “Buy” in the context of its long-term pipeline strength, though they flag regulatory overhangs as a near-term risk factor. In terms of institutional sentiment, data from Refinitiv indicates no major shifts in fund flow allocations into or out of Bayer’s healthcare segment in the past week, suggesting a holding pattern rather than a loss of confidence.

What’s next for elinzanetant’s U.S. launch?

Assuming a 90-day review extension, Bayer could receive a final FDA decision on elinzanetant before the end of Q4 2025. If approved, U.S. commercialization under the Lynkuet brand name would likely begin in early 2026, subject to logistics, payer negotiations, and clinician education campaigns.

Preparations for launch appear to be underway, with Bayer reportedly scaling its North America medical affairs and commercial operations specific to menopause care. Key opinion leader engagement, formulary discussions, and digital awareness campaigns are expected to ramp up through fall 2025.

Analysts expect Bayer to pursue an aggressive education strategy that includes direct-to-consumer advertising, provider education modules, and health system partnerships—particularly targeting OB/GYN networks and midlife health specialists.

If elinzanetant clears final regulatory hurdles in the U.S., it could become a flagship product not only in Bayer’s women’s health division but also within the broader neuroendocrine therapeutic landscape. Its success could also set a new precedent for CNS-modulating treatments in non-psychiatric domains, an area of increasing interest across big pharma.